Chronic myeloid leukemia stem cell biology

Current Hematologic Malignancy Reports

Volumn 7, Issue 2, 2012, Pages 125-132

  Crews, Leslie A ^a   Jamieson, Catriona H M ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

BCR ABL; Blast crisis; Bone marrow niche; Cell cycle; Chronic myeloid leukemia; CML; Hematologic malignancies; Hematopoiesis; Hematopoietic progenitors; Leukemia stem cell; LSC; Malignant; Quiescence; Self renewal; Shh . BCL2; Signal transduction; Splicing . Microenvironment; Survival; Therapeutic resistance .RNA; TKI . Imatinib; Tyrosine kinase inhibitors

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; BLAST CELL CRISIS; CANCER GROWTH; CANCER RELAPSE; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL RENEWAL; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; EPIGENETICS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; RNA PROCESSING; SIGNAL TRANSDUCTION; STEM CELL; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; BLAST CRISIS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS;

EID: 84860834388     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-012-0121-6     Document Type: Article

References (45)

1. Jamieson C. The MLLgnant consequences of reverting to an embryonic transcriptional program. Cell Stem Cell. 2009;4 (2):97-8.
2. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85-109.
3. Ben-Neriah Y, Daley GQ, Mes-Masson AM, et al. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986;233 (4760):212-4. (Pubitemid 16008117)
4. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315 (6020):550-4. (Pubitemid 15021190)
5. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med. 1977;63 (1):125-30. (Pubitemid 8146659)
6. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351 (7):657-67. (Pubitemid 39063268)
7. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med. 2003;348 (11):994-1004. (Pubitemid 36302244)
8. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol. 2010;11 (11):1029-35. This study highlights the role of therapeutically resistant LSC in progression and relapse of disease in patients with CML.
9. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107 (11):4532-9. (Pubitemid 43801382)
10. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99 (1):319-25.
11. Minami Y, Stuart SA, Ikawa T, et al. BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci U S A. 2008;105 (46):17967-72.
12. Grimmler M, Wang Y, Mund T, et al. Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell. 2007;128 (2):269-80. (Pubitemid 46123508)
13. Chiodoni C, Colombo MP, Sangaletti S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev. 2010;29 (2):295-307.
14. Essers MA, Trumpp A. Targeting leukemic stem cells by breaking their dormancy. Mol Oncol. 2010;4 (5):443-50.
15. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood. 2009;114 (6):1150-7.
16. Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010;464 (7290):852-7. This study shows that primary stromal dysfunction due to ablation of the Dicer1 gene can result in secondary neoplastic disease, supporting the concept of nicheinduced oncogenesis. This is one of recent seminal studies that underscores the importance of the malignant niche in leukemia development and progression.
17. Mendez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466 (7308):829-34. This study defines the partnership between somatic and hematopoietic cells indicative of aunique niche in the bone marrow made of heterotypic stem-cell pairs. This highlights the bidirectional nature of interactions between hematopoietic cells and the cellular components of the surrounding stromal microenvironment.
18. Jin L, Tabe Y, Konoplev S, et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther. 2008;7 (1):48-58.
19. Abrahamsson AE, Geron I, Gotlib J, et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci U S A. 2009;106 (10):3925-9.
20. Trowbridge JJ, Moon RT, Bhatia M. Hematopoietic stem cell biology: too much of a Wnt thing. Nat Immunol. 2006;7 (10): 1021-3. (Pubitemid 44420645)
21. Zhao C, Blum J, Chen A, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007;12 (6):528-41. (Pubitemid 350199070)
22. Hu Y, Chen Y, Douglas L, Li S. Beta-catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia. 2009;23 (1):109-16.
23. Taipale J, Beachy PA. The hedgehog and Wnt signalling pathways in cancer. Nature. 2001;411 (6835):349-54. (Pubitemid 32467044)
24. Ruiz i Altaba A, Sanchez P, Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer. 2002;2 (5):361-72. (Pubitemid 37328949)
25. Ingham PW. Transducing hedgehog: the story so far. EMBO J. 1998;17 (13):3505-11. (Pubitemid 28327369)
26. Trowbridge JJ, Scott MP, Bhatia M. Hedgehog modulates cell cycle regulators in stem cells to control hematopoietic regeneration. Proc Natl Acad Sci U S A. 2006;103 (38):14134-9. (Pubitemid 44452992)
27. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006;103 (8):2794-9.
28. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324 (5933):1457-61.
29. Duman-Scheel M, Weng L, Xin S, Du W. Hedgehog regulates cell growth and proliferation by inducing cyclin D and cyclin E. Nature. 2002;417 (6886):299-304. (Pubitemid 34534713)
30. Sengupta A, Banerjee D, Chandra S, et al. Deregulation and cross talk among sonic hedgehog,Wnt, Hox and notch signaling in chronic myeloid leukemia progression. Leukemia. 2007;21 (5):949-55.
31. Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117 (21):e198-206.
32. Perrotti D, Neviani P. From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way. Clin Cancer Res. 2007;13 (6):1638-42. This report provides evidence supporting the utility of targeting aberrant mRNA processing mechanisms in the development of alternative therapies for imatinib-resistant and blast crisis CML. (Pubitemid 46952928)
33. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478 (7367):64-9.
34. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365 (15):1384-95. This is one of the first studies to identify genetic abnormalities in a component of the cellular splicing machinery that contributes to myeloid abnormalities.
35. Hahn CN, Scott HS. Spliceosome mutations in hematopoietic malignancies. Nat Genet. 2011;44 (1):9-10.
36. Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120 (7):2254-64.
37. Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138 (2):271-85.
38. Rice KN, Jamieson CH. Molecular pathways to CML stem cells. Int J Hematol. 2010;91 (5):748-52.
39. Olivero S, Maroc C, Beillard E, et al. Detection of different ikaros isoforms in human leukaemias using real-time quantitative polymerase chain reaction. Br J Haematol. 2000;110 (4):826-30.
40. Vassen L, Khandanpour C, Ebeling P, et al. Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia. Int J Hematol. 2009;89 (4):422-30.
41. Drummond MW, Hoare SF, Monaghan A, et al. Dysregulated expression of the major telomerase components in leukaemic stem cells. Leukemia. 2005;19 (3):381-9. (Pubitemid 40403314)
42. Ma W, Giles F, Zhang X, et al. Three novel alternative splicing mutations in BCR-ABL1 detected in CML patients with resistance to kinase inhibitors. Int J Lab Hematol. 2011;33 (3):326-31.
43. Salesse S, Dylla SJ, Verfaillie CM. p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells. Leukemia. 2004;18 (4):727-33. (Pubitemid 38500190)
44. Bahn JH, Lee JH, Li G, et al. Accurate identification of A-to-I RNA editing in human by transcriptome sequencing. Genome Res. 2011.
45. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in alobular breast tumour profiled at single nucleotide resolution. Nature. 2009;461 (7265):809-13.